Ayr Strategies Competitors

Ayr Strategies (OTCMKTS:AYRSF) and Abacus Health Products (OTCMKTS:ABAHF) are both medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, dividends, profitability, earnings, analyst recommendations, risk and institutional ownership.

Profitability

This table compares Ayr Strategies and Abacus Health Products' net margins, return on equity and return on assets.

Analyst Ratings

This is a summary of recent ratings and recommmendations for Ayr Strategies and Abacus Health Products, as reported by MarketBeat.

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, analysts clearly believe Ayr Strategies is more favorable than Abacus Health Products.

Earnings and Valuation

This table compares Ayr Strategies and Abacus Health Products' top-line revenue, earnings per share and valuation.

Summary

Ayr Strategies beats Abacus Health Products on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Acreage (OTCMKTS:ACRGF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Acreage's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ayr Strategies and Acreage's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Acreage, as reported by MarketBeat.com.

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Acreage has a consensus price target of $8.4333, suggesting a potential upside of 204.45%. Given Acreage's higher probable upside, analysts plainly believe Acreage is more favorable than Ayr Strategies.

Summary

Ayr Strategies beats Acreage on 2 of the 3 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Applied Biosciences (OTCMKTS:APPB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Applied Biosciences' net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ayr Strategies and Applied Biosciences' top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Applied Biosciences, as reported by MarketBeat.com.

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Applied Biosciences.

Summary

Ayr Strategies beats Applied Biosciences on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Can B (NASDAQ:CANB) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Profitability

This table compares Ayr Strategies and Can B's net margins, return on equity and return on assets.

Earnings & Valuation

This table compares Ayr Strategies and Can B's top-line revenue, earnings per share and valuation.

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Can B, as reported by MarketBeat.com.

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Can B.

Summary

Ayr Strategies beats Can B on 2 of the 2 factors compared between the two stocks.

Ayr Strategies (OTCMKTS:AYRSF) and Cansortium (OTCMKTS:CNTMF) are both medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, dividends, analyst recommendations, earnings, risk, valuation and institutional ownership.

Earnings & Valuation

This table compares Ayr Strategies and Cansortium's top-line revenue, earnings per share and valuation.

Profitability

This table compares Ayr Strategies and Cansortium's net margins, return on equity and return on assets.

Analyst Recommendations

This is a summary of recent recommendations for Ayr Strategies and Cansortium, as reported by MarketBeat.com.

Ayr Strategies currently has a consensus price target of $34.8571, suggesting a potential upside of 63.96%. Cansortium has a consensus price target of $1.20, suggesting a potential upside of 35.90%. Given Ayr Strategies' higher probable upside, equities research analysts plainly believe Ayr Strategies is more favorable than Cansortium.

Summary

Ayr Strategies beats Cansortium on 2 of the 3 factors compared between the two stocks.

Charlotte's Web (OTCMKTS:CWBHF) and Ayr Strategies (OTCMKTS:AYRSF) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, institutional ownership, profitability and earnings.

Analyst Recommendations

This is a breakdown of current recommendations and price targets for Charlotte's Web and Ayr Strategies, as provided by MarketBeat.

Charlotte's Web presently has a consensus target price of $7.25, suggesting a potential upside of 73.44%. Ayr Strategies has a consensus target price of $34.8571, suggesting a potential upside of 63.96%. Given Charlotte's Web's higher possible upside, analysts plainly believe Charlotte's Web is more favorable than Ayr Strategies.

Earnings and Valuation

This table compares Charlotte's Web and Ayr Strategies' gross revenue, earnings per share (EPS) and valuation.

Profitability

This table compares Charlotte's Web and Ayr Strategies' net margins, return on equity and return on assets.

Summary

Ayr Strategies beats Charlotte's Web on 2 of the 3 factors compared between the two stocks.